ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BUR Burford Capital Limited

1,079.00
12.00 (1.12%)
Last Updated: 12:37:42
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Burford Capital Limited LSE:BUR London Ordinary Share GG00BMGYLN96 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.00 1.12% 1,079.00 1,077.00 1,080.00 1,090.00 1,067.00 1,067.00 44,938 12:37:42
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Unit Inv Tr, Closed-end Mgmt 1.39B 610.52M - N/A 2.33B
Burford Capital Limited is listed in the Unit Inv Tr, Closed-end Mgmt sector of the London Stock Exchange with ticker BUR. The last closing price for Burford Capital was 1,067p. Over the last year, Burford Capital shares have traded in a share price range of 975.50p to 1,387.00p.

Burford Capital currently has 218,646,081 shares in issue. The market capitalisation of Burford Capital is £2.33 billion.

Burford Capital Share Discussion Threads

Showing 11276 to 11292 of 26225 messages
Chat Pages: Latest  461  460  459  458  457  456  455  454  453  452  451  450  Older
DateSubjectAuthorDiscuss
16/8/2019
16:01
Jefferies have recommended BUY with a target price of £24. Pity the market hasn't reacted to that yet!!
fairbear
16/8/2019
16:00
You are great at conjecture SK, you literally make up assumptions and try to relay them as factual.
ozzmosiz
16/8/2019
15:48
From Burford's 2013 annual report, interesting that they decided to comment specifically on arbitration and to say that it has potentially higher returns: The international arbitration market is quite
different than either domestic litigation market
in which we are active. Arbitration matters settle
less frequently than litigation matters, and as a
result fewer matters produce positive outcomes
for claimants. Moreover, because arbitrations
more often end in awards than settlements
compared to domestic litigation, there tends to
be more enforcement activity to get to cash
receipts. On the other hand, arbitration often is
less expensive than the comparable domestic
litigation proceeding, and can be faster,
although disappointing trends in investor-state
arbitration are eroding both of those
advantages. These structural dynamics tend to
result in capital for arbitrations being priced
higher than for comparable domestic litigation
matters and for loss rates similarly to be higher.
We remain enthusiastic about arbitration
fiance for a number of reasons. We have a
clear brand position in the arbitration fild
– and the area is suffiiently specialised that
there are only a modest number of competitors.
Arbitration permits us to expand our
international reach without needing
to become enmeshed in the domestic litigation
environment of other countries, and we have
thus far been able to achieve the kind of
economic terms that compensate for the
higher loss rates

dgdg1
16/8/2019
15:40
Hang on a minute, SK.

$15.8m was the total recovered. The gain (or BUR's cut as you put it) was "only" $8.4m. So how could $8.4m have been generated, given that Napo refers to "a successful outcome in the litigation"? It doesn't seem that outrageous in the scheme of things, does it?

Also, I would say that $15.8m was a fairly material figure in relation to the 2013 accounts, and there really weren't that many claims to look at. You will be sceptical I'm sure, but it would seem inconceivable that the auditors would not have been looking at it very closely and certainly at the existence and substance of the transaction.

achenaton
16/8/2019
15:34
Next Friday 900's maybe even back in double figures. October £14ish per share.This time next year £27.45 with American listing.
hawkind
16/8/2019
15:26
DAF,Last weekend, I would agree with you, this weekend after BUR's RNS this week there is now no risk whatsoever in the medium term.
hawkind
16/8/2019
15:20
Yes, MW went short American Tower in 2013. It took months to recover from that BS and it has tripled since... Most of the points were same as BUR... Yes, let's go and buy more BUR so we can kick their a... I am buying everyday!

You can see their short here

thedisciplinedinvestor
16/8/2019
15:18
What do you think of adnan's latest find?
dgdg1
16/8/2019
15:16
Bond holders clearly not convinced by governance changes as bonds still drifting along at significant discounts to par.
sweet karolina2
16/8/2019
15:16
As i said i have no intention of investing either way
dafad
16/8/2019
15:15
Must admit that i bought after the first repprt came out and ended up with an average price of £8.20,today i sold the lot and came out with beer money as profit!!

At the moment its to risky for me-I hope investors do well.

ButI would urge investors to read up on Noble from 2014-2018 ,it has all the main short characters that we have here,no advice intended .Gla

dafad
16/8/2019
15:14
Utterly bizarre price action; it makes no sense. Yesterday they release one of the best RNS I've seen on AIM and yet we're down 8% today. BS. Nobody is having my shares.
mryl
16/8/2019
15:12
The only way to stop this bleeding is to get buyers of the stock. People who are in are not buying more. Those who sold in panic mode are not coming back. Institutions are on the sidelines. As long as BUR does not convince buyers or start a buyback program the sell-off will go on
thedisciplinedinvestor
16/8/2019
15:11
The only way to stop this bleeding is to get buyers of the stock. People who are in are not buying more. Those who sold in panic mode are not coming back. Institutions are on the sidelines. As long as BUR does not convince buyers or start a buyback program the sell-off will go on
thedisciplinedinvestor
16/8/2019
15:07
Lol

And I quote:

"Napo believes Glenmark has materially breached the Collaboration Agreement by failing to fulfill its basic responsibilities to develop and commercialize this important drug,” says William A. Brewer III, partner at Bickel & Brewer and counsel for Napo. “Most notably, Glenmark has not filed a single application to register this drug in any country in the world, despite having had the license for more than six years.”

On September 9, 2011, Napo sent Glenmark a notice of default, which gave Glenmark 60 days to remedy its defaults alleged therein. Napo terminated the agreement based on Glenmark’s failure to cure these defaults.

So Glenmark were not doing developing and commercialising. Court forced them to develop and commercialise."

hxxps://www.businesswire.com/news/home/20111212006268/en/Napo-Terminates-Glenmark-Pharmaceuticals-Failure-Commercially-Develop

How does that not have value?

adnan17
16/8/2019
15:07
can we see a big Whoosh coming ?
pal44
16/8/2019
15:04
nicely said winsome
ozzmosiz
Chat Pages: Latest  461  460  459  458  457  456  455  454  453  452  451  450  Older

Your Recent History

Delayed Upgrade Clock